{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRA&page=9", "query": { "intervention": "MRA", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 272, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRA&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRA&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T17:13:04.306Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01010932", "title": "Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Arterial Diseases" ], "interventions": [ { "name": "Dotarem", "type": "DRUG" }, { "name": "TOF MRA", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2009-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2016-06-16", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 1, "location_summary": "Bloomington, Indiana", "locations": [ { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010932" }, { "nct_id": "NCT00001841", "title": "Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atherosclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "1999-03", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001841" }, { "nct_id": "NCT04616248", "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Unresectable Breast Carcinoma", "Metastatic Melanoma", "Unresectable Melanoma", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Soft Tissue Sarcoma", "Bone Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma of Bone", "Basal Cell Carcinoma" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-09", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616248" }, { "nct_id": "NCT01012674", "title": "Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Arterial Diseases" ], "interventions": [ { "name": "Dotarem", "type": "DRUG" }, { "name": "TOF MRA", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2009-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2016-06-16", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 1, "location_summary": "Bloomington, Indiana", "locations": [ { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012674" }, { "nct_id": "NCT03193190", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "PEGPH20", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "RO6874281", "type": "DRUG" }, { "name": "AB928", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2017-07-05", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 12, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03193190" }, { "nct_id": "NCT03671018", "title": "A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab (IV)", "type": "DRUG" }, { "name": "Mosunetuzumab (SC)", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2018-09-25", "completion_date": "2025-07-20", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03671018" }, { "nct_id": "NCT00980681", "title": "Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Disease" ], "interventions": [ { "name": "Dotarem", "type": "DRUG" }, { "name": "Time of Flight", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2016-05-26", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 1, "location_summary": "Bloomington, Indiana", "locations": [ { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980681" }, { "nct_id": "NCT04580121", "title": "A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "RO7283420", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Paracetamol/acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2020-11-04", "completion_date": "2023-08-09", "has_results": false, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 2, "location_summary": "Sacramento, California • Houston, Texas", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580121" }, { "nct_id": "NCT01475162", "title": "Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Graft Versus Host Disease" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2011-08-08", "completion_date": "2018-09-29", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475162" }, { "nct_id": "NCT00590980", "title": "Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Vertebrobasilar Insufficiency", "Ischemic Attack, Transient", "Cerebrovascular Disorder", "Brain Ischemia", "Stroke" ], "interventions": [], "intervention_types": [], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2008-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-25T17:13:04.306Z", "location_count": 5, "location_summary": "Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590980" } ] }